Vortioxetine for Cancer Patients With Depression: An Observational Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04253678|
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : February 5, 2020
|Condition or disease||Intervention/treatment|
|Major Depressive Disorder Cancer||Drug: Vortioxetine|
Cancer is always a feared illness and the diagnosis of cancer has huge psychological impact on the patients. Depression is one of the most common psychiatric sequelae and affects the disease outcome in cancer patients. Along with depression, cancer patients are also vulnerable to develop cognitive impairment. It could be related to the cancer or its treatment. Cognitive impairment that occurs among cancer patient is known as cancer related cognitive impairment (CRCI). Depression together with cognitive impairment adversely affect the quality of life of cancer patients. To date, the optimal treatment of depression in cancer is not established. The number of studies investigated the efficacy of pharmacotherapy for depression in cancer patient is limited. The evidence of treatment for cognitive impairment in depressed cancer patients is even more scarce.
Vortioxetine is one of the latest marketed antidepressants in Malaysia. It has numerous additional effects as compared to other conventional antidepressants. In addition to blockade of the serotonin transporter (SERT), vortioxetine has affinity for 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors and as such, it is described as a 'multimodal serotonin modulator'. This may explain the additional benefit of vortioxetine in the treatment of depression as compared to other antidepressants. Furthermore, the unique mechanism of action of vortioxetine was also reported to improve cognitive function in patients with depression.
To examine the effect of vortioxetine in improving the depressive symptoms, cognitive impairment and quality of life in cancer patients who have major depressive disorder.
- To determine whether treatment with antidepressant vortioxetine is effective to improve depressive symptoms in patients diagnosed with cancer (of any origin) and major depressive disorder.
- To determine whether treatment with antidepressant vortioxetine is effective to improve cognitive impairment in patients diagnosed with cancer (of any origin) and major depressive disorder.
- To determine whether treatment with antidepressant vortioxetine is effective to improve quality of life in patients diagnosed with cancer (of any origin) and major depressive disorder.
|Study Type :||Observational|
|Estimated Enrollment :||140 participants|
|Official Title:||Vortioxetine for Cancer Patients With Depression: An Observational Study|
|Actual Study Start Date :||December 12, 2019|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||July 2020|
Study participants will be started on a flexible-dose of vortioxetine (5-20 mg) followed by a baseline assessment of primary outcomes using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Perceived Deficit Questionnaire - 5 items (PDQ-5), and secondary outcomes using the EORTC Quality of life Questionnaire (QLQ-C30) and Clinical Global Impression (CGI). The assessment timelines will be at week 2, week 4, week 8, and week 12.
Side effects, if any, will be recorded using the Antidepressant Side-effect Checklist (ASEC).
Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
Other Name: Brintellix
- Changes in Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: baseline (week 1), week 2, week 4, week 8, week 12 ]The MADRS is a widely used clinical rating scale for depression. It consists of 10 items evaluating core symptoms of depression (Montgomery & Äsberg, 1979; Montgomery et al., 1978). Nine of the items are based upon patient report, and one is on the rater's observation during the rating interview. MADRS items are rated on a 0-6 continuum (0=no abnormality, 6=severe). The MADRS is relatively quick to administer and addresses core mood symptoms of depression such as sadness, tension, lassitude, pessimistic thoughts, and suicidal thoughts.
- Changes in Perceived Deficits Questionnaire - 5 items (PDQ-5) [ Time Frame: baseline (week 1), week 2, week 4, week 8, week 12 ]The PDQ-5 is a brief patient-rated scale to assess subjective cognitive dysfunction in people with depression. The PDQ originally is a 20-item questionnaire developed by Dr. Michael Sullivan at McGill University as a scale for use in patients with multiple sclerosis that generates a total score and 4 subscale scores (attention/concentration, retrospective memory, prospective memory, and planning/organization) (Sullivan et al., 1990). A 5-item version (PDQ-D-5) is a brief version and has been adapted and validated for use in patients with major depressive disorder.
- Changes in Clinical Global Impression (CGI) [ Time Frame: baseline (week 1), week 2, week 4, week 8, week 12 ]The CGI allows psychiatrist to assess the patient's condition relative to baseline and rate the change on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
- Changes in EORTC-QLQ-C30 [ Time Frame: baseline (week 1), week 2, week 4, week 8, week 12 ]The EORTC QLQ-C30 is widely used clinical scale for measurement of cancer-specific quality of life. It contains five functioning scales (physical, social, role, cognitive, and emotional functioning), eight symptom scales (fatigue, nausea/vomiting, pain, dyspnea, sleep disturbances, appetite loss, constipation, and diarrhea), financial impact, and overall quality of life. All scale scores are linearly converted to range from 0 to 100. For the functioning scales and global QOL higher scores indicate better functioning; for the symptom scales higher scores indicate higher symptom burden (Aaronson et al., 1993).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04253678
|Contact: Chong Guan Ng||012 3408 email@example.com|
|Contact: Sue-Yin Low||010 226 firstname.lastname@example.org|
|Hospital Raja Permaisuri Bainun, Ipoh||Not yet recruiting|
|Ipoh, Perak, Malaysia, 30450|
|Contact: Tsui Huei Loo email@example.com|
|Sub-Investigator: Tsui Huei Loo|
|Hospital Tengku Ampuan Rahimah Klang||Not yet recruiting|
|Klang, Selangor, Malaysia, 41200|
|Contact: Natasha Subhas firstname.lastname@example.org|
|Sub-Investigator: Natasha Subhas|
|Hospital Sungai Buloh||Not yet recruiting|
|Sungai Buloh, Selangor, Malaysia, 47000|
|Contact: Chung Wah Lee email@example.com|
|Contact: Muhammad Najib bin Abdullah firstname.lastname@example.org|
|Sub-Investigator: Chung Wah Lee|
|Sub-Investigator: Muhammad Najib bin Abdullah|
|National Cancer Institute||Recruiting|
|Kuala Lumpur, Malaysia, 50300|
|Contact: Kai Shin Thong email@example.com|
|Sub-Investigator: Kai Shin Thong|
|Hospital Kuala Lumpur||Recruiting|
|Kuala Lumpur, Malaysia, 50586|
|Contact: Sapini binti Yacob firstname.lastname@example.org|
|Sub-Investigator: Sapini binti Yacob|
|Pusat Perubatan Universiti Kebangsaan Malaysia||Recruiting|
|Kuala Lumpur, Malaysia, 56000|
|Contact: Nik Ruzyanei Nik Jaafar email@example.com|
|Sub-Investigator: Nik Ruzyanei Nik Jaafar|
|Sub-Investigator: Nurul Ain binti Mohamad Kamal|
|University Malaya Medical Centre||Recruiting|
|Kuala Lumpur, Malaysia, 59100|
|Contact: Chong Guan Ng 012 3408 813 firstname.lastname@example.org|
|Contact: Sue-Yin Low 010 226 3861 email@example.com|
|Principal Investigator: Chong Guan Ng|
|Sub-Investigator: Sue-Yin Low|
|Sub-Investigator: Aya Ahmed Abousheishaa|
|Sub-Investigator: Nor Zuraida Zainal|
|Kuala Lumpur, Malaysia, 62250|
|Contact: Kai Shin Thong firstname.lastname@example.org|
|Contact: Azizul bin Awaluddin email@example.com|
|Sub-Investigator: Kai Shin Thong|
|Sub-Investigator: Azizul bin Awaluddin|
|Principal Investigator:||Chong Guan Ng||UMMC|